{"title":"缺氧诱导因子-脯氨酸-羟化酶抑制剂停药后暂时性红细胞功能低下。","authors":"Masayuki Tanemoto","doi":"10.1111/hdi.13258","DOIUrl":null,"url":null,"abstract":"<p><p>Recently, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been introduced as a therapeutic option for anemia, a common complication of chronic kidney disease. Although HIF-PHIs demonstrate efficacy in managing anemia, their administration may lead to dependence on upregulated hypoxia-inducible factors. Here, we report two maintenance hemodialysis cases that experienced temporary erythropoiesis hypoactivity following HIF-PHI discontinuation.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Temporary Erythropoiesis Hypoactivity Following Hypoxia-Inducible-Factor-Prolyl-Hydroxylase-Inhibitor Discontinuation.\",\"authors\":\"Masayuki Tanemoto\",\"doi\":\"10.1111/hdi.13258\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recently, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been introduced as a therapeutic option for anemia, a common complication of chronic kidney disease. Although HIF-PHIs demonstrate efficacy in managing anemia, their administration may lead to dependence on upregulated hypoxia-inducible factors. Here, we report two maintenance hemodialysis cases that experienced temporary erythropoiesis hypoactivity following HIF-PHI discontinuation.</p>\",\"PeriodicalId\":94027,\"journal\":{\"name\":\"Hemodialysis international. International Symposium on Home Hemodialysis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hemodialysis international. International Symposium on Home Hemodialysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/hdi.13258\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemodialysis international. International Symposium on Home Hemodialysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/hdi.13258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Temporary Erythropoiesis Hypoactivity Following Hypoxia-Inducible-Factor-Prolyl-Hydroxylase-Inhibitor Discontinuation.
Recently, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been introduced as a therapeutic option for anemia, a common complication of chronic kidney disease. Although HIF-PHIs demonstrate efficacy in managing anemia, their administration may lead to dependence on upregulated hypoxia-inducible factors. Here, we report two maintenance hemodialysis cases that experienced temporary erythropoiesis hypoactivity following HIF-PHI discontinuation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
